Log in

NASDAQ:RIGL - Rigel Pharmaceuticals Stock Price, Forecast & News

-0.03 (-1.33 %)
(As of 12/15/2019 01:29 AM ET)
Today's Range
Now: $2.23
50-Day Range
MA: $2.22
52-Week Range
Now: $2.23
Volume1.22 million shs
Average Volume1.17 million shs
Market Capitalization$373.77 million
P/E RatioN/A
Dividend YieldN/A
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RIGL



Sales & Book Value

Annual Sales$44.51 million
Book Value$0.66 per share


Net Income$-70,480,000.00


Market Cap$373.77 million
Next Earnings Date2/27/2020 (Estimated)

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. The biotechnology company had revenue of $20.86 million for the quarter, compared to the consensus estimate of $16.27 million. Rigel Pharmaceuticals had a negative return on equity of 52.74% and a negative net margin of 56.84%. During the same period last year, the firm earned ($0.14) EPS. View Rigel Pharmaceuticals' Earnings History.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Rigel Pharmaceuticals.

What price target have analysts set for RIGL?

4 Wall Street analysts have issued 1-year price objectives for Rigel Pharmaceuticals' stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate Rigel Pharmaceuticals' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 236.3% from the stock's current price. View Analyst Price Targets for Rigel Pharmaceuticals.

What is the consensus analysts' recommendation for Rigel Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rigel Pharmaceuticals.

What are Wall Street analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (11/9/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $7 PT on Rigel following results from the period ended 3/31/2019. During the quarter, Rigel reported sales of $8.1 million for TAVALISSE for the treatment of immune thrombocytopenia (ITP), which was a slight beat vs. our $7.7 million estimate. Our near-term focus for Rigel will remain on quarterly U.S. sales for TAVALISSE. Additionally, we await an EU approval decision by year-end 2019, which could expand the revenue opportunity for Rigel and provide upfront capital of nearly $40 million from Grifols (GRFS – NC)." (5/7/2019)

Has Rigel Pharmaceuticals been receiving favorable news coverage?

Media coverage about RIGL stock has trended extremely negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Rigel Pharmaceuticals earned a daily sentiment score of -5.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Rigel Pharmaceuticals.

Are investors shorting Rigel Pharmaceuticals?

Rigel Pharmaceuticals saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 11,250,000 shares, an increase of 7.3% from the November 14th total of 10,480,000 shares. Based on an average daily trading volume, of 1,500,000 shares, the short-interest ratio is currently 7.5 days. Approximately 6.9% of the company's shares are sold short. View Rigel Pharmaceuticals' Current Options Chain.

Who are some of Rigel Pharmaceuticals' key competitors?

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include Rite Aid (RAD), Terra Tech (TRTC), Synergy Pharmaceuticals (SGYP), Geron (GERN), Inovio Pharmaceuticals (INO), Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Verastem (VSTM), Athersys (ATHX) and Fate Therapeutics (FATE).

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the folowing people:
  • Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 58)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 54)
  • Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 60)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 58)
  • Dr. Thomas A. Raffin, Co-Founder (Age 72)

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (4.56%), State Street Corp (2.03%), Rhenman & Partners Asset Management AB (1.19%), Squarepoint Ops LLC (0.66%), Assenagon Asset Management S.A. (0.37%) and California Public Employees Retirement System (0.31%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Dean L Schorno, Eldon C Mayer III, Nelson Cabatuan and Raul R Rodriguez. View Institutional Ownership Trends for Rigel Pharmaceuticals.

Which institutional investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Assenagon Asset Management S.A., Rhenman & Partners Asset Management AB, Russell Investments Group Ltd., Alps Advisors Inc. and Metropolitan Life Insurance Co NY. View Insider Buying and Selling for Rigel Pharmaceuticals.

Which institutional investors are buying Rigel Pharmaceuticals stock?

RIGL stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, California Public Employees Retirement System, Barclays PLC, Meeder Asset Management Inc., SG Americas Securities LLC, Brighton Jones LLC and California State Teachers Retirement System. Company insiders that have bought Rigel Pharmaceuticals stock in the last two years include Dean L Schorno, Eldon C Mayer III and Raul R Rodriguez. View Insider Buying and Selling for Rigel Pharmaceuticals.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $2.23.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $373.77 million and generates $44.51 million in revenue each year. The biotechnology company earns $-70,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Rigel Pharmaceuticals employs 158 workers across the globe.View Additional Information About Rigel Pharmaceuticals.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is http://www.rigel.com/.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]

MarketBeat Community Rating for Rigel Pharmaceuticals (NASDAQ RIGL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  376 (Vote Outperform)
Underperform Votes:  287 (Vote Underperform)
Total Votes:  663
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe RIGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel